Ann: Travelan to progress to Phase 3 Clinical Trials in the US, page-69

Not sure if anyone else is watching the US markets but behaving as predicted. In the first hour of trading it went from opening at around $3, dipping to $2.75, then rocketing to $5.50. It's now at $3.80. At $5.50 it was up 230% on previous close.

For reference, 550/40/.66 = 21c on the ASX.

Betting on the stock skyrocketing in the US was a no brainer IMO given that there's many more punters playing the US stock market compared to the ASX - but there's only half as many Immuron shares on issue there. If it rocketed 100% on the ASX with double the supply of shares and a tiny fraction of traders, no surprise it's going to go even higher in the US.

Just absolutely steamrolling past what I thought was the logical conclusion of the announcement. The conclusion being the once daily drug hasn't performed anywhere near as strongly as the 3 times daily version, perhaps a natural consequence of the fact that anything you ingest in the morning will be mostly digested, and in miniscule concentrations in your stomach, by dinner time in the evening.

disc: I don't hold any IMC shares but ticking held anyway because I bought some IMRN in the US on open